List of Regenerative Medicine Companies in Belgium - 6

4Tissue is an innovation-led research and clinical development organization. Our mission is to redefine the boundaries of tissue reconstruction, regeneration, and anti-aging, utilizing innovative biocompatible and bioresorbable polymers platform The first product, a bioresorbable injectable hydrogel, is focused on a better cell survival and the full regeneration of adipose tissue for breast reconstruction and augmentation applications.

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

We are Antleron, a nimble team that will revolutionise medicine by leading the development of next generation advanced therapies and medical devices. By merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors we will accelerate the engineering of medicinal products, devices and processes that will change health care and result in a better life for all. The Antleron business philosophy is to create sustainable ventures through risk & reward sharing partnerships based on the adoption of our game changing team know-how and technology platforms.

KiOmed Pharma is a biotechnology company based in Belgium that focuses on developing, manufacturing, and distributing chitosan-based medical devices. The company, a spinout from KitoZyme, utilizes exclusive natural chitosan chemistry to create solutions for high-impact medical conditions, particularly in osteoarthritis, dermatology, and ophthalmology. Headquartered in Herstal, Liège, KiOmed Pharma emphasizes therapeutic innovations through its proprietary KiOmedine® technology platform. One of its key products is KioMedine(vs)one, a single-injection soft implant designed to relieve pain and improve mobility in knee osteoarthritis patients. The company is also developing additional products targeting joint health, skin aging, and eye-related disorders. KiOmed Pharma maintains a commitment to biocompatibility and safety by using non-animal-derived chitosan in its formulations. In April 2024, KiOmed Pharma formed a strategic alliance with Aptissen to globally commercialize KioMedine(vs)one, enhancing patient access to its treatments while generating revenue through royalties and milestone payments. Under the leadership of CEO Houtaï Choumane, the company aims to create long-term value and improve patient outcomes in chronic diseases.

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition.

RevaTis and University of Liège have developed and patented a specific procedure for the collection, production and storage of autologous muscle-derived mesenchymal stem cells (MdMSC) for immediate therapeutic use or storage for further processing. RevaTis technology is minimally invasive and offers benefits for generating a large number of autologous stem cells. Our sustainable avantages: - patents granted for obtaining pluripotent stem cells by a minimally invasive method for human and veterinary medicine - GMP production in aseptic isolator - Authorization for the production of batches in veterinary and human medicine for clinical studies or research - Accredited stem cell tissue-banks Our Market: The global market for stem cell treatments in animals has a growing rate annual average of 37.27% between 2017 and 2025 and will reach more than 200.000.000 €. In 2017, the global market for equine-level cell therapy was estimated at one third of the global market, In Human Medicine, RevaTis will focuse on the segment "Stem Cell Research and Services. This segment was $ 1,300 million in 2017 to arrive at a size estimate of market of $ 2,400 million in 2022. Our customers: In Vet Medicine, after the approval by agencies, our potential customer are the veterinarians. For Human Application, our markets include partners involved in - R&D Programs on Regenerative Medicine and Cell Therapy - Tissu engineering and 3D-Bio-Printing - Organ on a chip technology. In other words, all companies or Resarch Centers looking for a sourcing of large quantities of MSCs easily to transer in clinic.